AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (Q38097423)
Jump to navigation
Jump to search
scientific article published on 08 April 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer |
scientific article published on 08 April 2013 |
Statements
1 reference
AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer (English)
1 reference
Luca Gianni
1 reference
Gilles H Romieu
1 reference
Michail Lichinitser
1 reference
Sergio V Serrano
1 reference
Mauro Mansutti
1 reference
Xavier Pivot
1 reference
Paola Mariani
1 reference
Fabrice Andre
1 reference
Arlene Chan
1 reference
Oleg Lipatov
1 reference
Stephen Chan
1 reference
Andrew Wardley
1 reference
Richard Greil
1 reference
Nicola Moore
1 reference
Sylvie Prot
1 reference
Celine Pallaud
1 reference
Vladimir Semiglazov
1 reference
8 April 2013
1 reference
1 reference
Identifiers
1 reference